

FREMEDICA LAUNCHES NIGHT-TIME WEARABLE THAT IMPROVES CELLULAR FUNCTION FOR BETTER SLEEP, LESS PAIN AND MORE ENERGY

VANCOUVER, BRITISH COLUMBIA – November 3, 2022 – Frequency Exchange Corp. (“Frequency Exchange” or the “Company”) (TSXV: FREQ) is pleased to announce that its wholly-owned subsidiary, FREmedica Technologies Inc. (“FREmedica”), a Canadian Wellness Company, has launched NIKKI, a Frequency Delivery System that supports recovery from wellness and performance issues while you sleep, into Canada USA and Europe.

Bioenergetics-based NIKKI emits frequencies that help restore cellular function within the body’s network of 37 trillion cells. NIKKI works at night to overcome physical and emotional trauma experienced during the day that may cause fatigue, pain, stress which will all affect your sleep.



A recent study found that 73% of all users in a Quality-of-Life trial showed significant improvement in mood, energy, and overall wellness during the trial. Learn more at www.WeAreNikki.com/Study-Results and preview Dr. Leigh Erin Connealy’s research findings and presentation on NIKKI.

Orders for an initial run of 5,000 NIKKI Frequency Delivery Systems that you wear, are being taken at www.WeAreNikki.com/product/nikki, with delivery scheduled for early December just in time for Christmas. Reservations and Orders have already started to come in.

Nicole Sullivan, President of FREmedica states, “This is an incredible time we live in and we as a company are excited to offer a \$250 NIKKI early-adopter pre-release price which includes the NIKKI Gold program, with your order in November. NIKKI will make a great gift for Christmas as it has been designed to support people to decrease pain, stress, fatigue, and poor sleep which we can all use some help with. Special offer ends December 1, 2022 so order today while NIKKI is available.”

About the Company

Based in British Columbia, Canada, the company is focused on the development and commercialization of a Frequency Delivery System that you wear, to markets worldwide, delivering specialized programs designed for health and wellness as well as performance enhancement. NIKKI is the fifth-generation Frequency Delivery System released by the Company. It is the third wearable technology created by the Company, initially to help clients with chronic Lyme disease. This wearable technology combined with the frequencies is the result of years of development and experimentation with the latest in bio-energetic technology.

www.WeAreNikki.com
www.Fremedica.com
www.FrequencyExchangeCorp.com

For more information, please contact:

Frequency Exchange Corp.

Stephen Davis
CEO & Director
250-732-7170

FREmedica Technologies Inc.

Nicole Sullivan
President
nicole@fremedica.com

Cautionary Note Regarding Forward-Looking Information

Certain information contained herein constitutes “forward-looking information” under Canadian securities legislation. Forward-looking information includes, but is not limited to, statements with respect to the trading date of the Company’s common shares on the Exchange. Generally, forward-looking information can be identified by the use of forward-looking terminology such as “will” or variations of such words and phrases or statements that certain actions, events or results “will” occur. Forward-looking statements are based on the opinions and estimates of management as of the date such statements are made and they are subject to known and unknown risks, uncertainties and other factors that may cause the actual results to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Readers should not place undue reliance on forward-looking statements and forward-looking information. The Company will not update any forward-looking statements or forward-looking information that are incorporated by reference herein, except as required by applicable securities laws.

Additional information identifying risks and uncertainties is contained in filings by the Company with the Canadian securities regulators, which filings are available under the Company’s profile on SEDAR at www.sedar.com.

Neither the Exchange nor its Regulation Services Provider (as that term is defined in policies of the Exchange) accepts responsibility for the adequacy or accuracy of this release.